Open label, uncontrolled, study of XRP9881 (Larotaxel) in combination with weekly trastuzumab (Herceptin) in patients with HER2 positive metastatic breast cancer (MBC)
Phase of Trial: Phase II
Latest Information Update: 09 May 2016
At a glance
- Drugs Larotaxel (Primary) ; Trastuzumab
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Sanofi
- 07 Jul 2009 Actual end date (1 Mar 2008) and actual patient number (6) added as reported by ClinicalTrials.gov.
- 26 Apr 2008 The expected completion date for this trial is now 1 May 2008.
- 14 Feb 2008 Status changed from recruiting to in progress, in accordance with clinicaltrials.gov.